在日本的儿科喘实践中,有非标签的吸入疗法的证据
Kenji Oishi1, Eisuke Inage2,3, Mayuki Kojima2
1Department of Pediatrics and Adolescent Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
概括
在日本,大量的喘吸入器被非标签处方给儿童. 吸入性皮质类固醇 (ICS) 或长效β兴奋剂 (LABA) 占这些处方中的大多数,突出了需要更好的指导方针和覆盖范围.
科学领域:
- 儿科肺病学 儿科肺病学
- 现实世界的证据 现实世界的证据
- 制药政策 制药政策
背景情况:
- 由于国内数据不足,许多喘吸入器在日本缺乏正式批准用于儿科.
- 在日本,非标签药物处方在儿科喘管理中很常见.
- 日本儿童使用非标注的喘吸入器的程度和性质之前尚不清楚.
研究的目的:
- 在日本的儿科患者中调查非标注的喘吸入器处方的现实世界描述性流行病学.
- 分析七年来非标签吸入器使用的趋势和模式.
主要方法:
- 利用公开可用的,开源的国家医疗索赔数据.
- 分析了自2014年4月起0-14岁患者的匿名总结处方数据.
- 检查了处方编号和它们在七年中的时间顺序.
主要成果:
- 2019年,143,439种喘吸入器被非标签处方给儿科患者.
- 吸入性皮质类固醇 (ICS) 或长效β兴奋剂 (LABA) 占这些非标签处方的96.1%.
- 虽然非标签ICS/LABA使用的整体趋势下降了,但不同类型的吸入器之间存在显著的差异.
结论:
- 对于日本的儿科患者而言,存在大量的非标签性喘吸入器处方.
- 建议包括倡导正确使用ICS/LABA,并扩大保险覆盖范围,以减轻非标签处方.
- 需要进一步的研究和政策变化,以确保为儿童提供适当的喘治疗.
相关概念视频
Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Asthma-IV: Nursing Management
3.1K
The nursing management of asthma is a comprehensive approach that relies heavily on the expertise and dedication of healthcare professionals. It involves thorough assessment, accurate diagnosis, strategic planning, effective implementation, and diligent evaluation. By meticulously following this step-by-step process, healthcare professionals play a crucial role in providing the best possible care and treatment for patients with asthma, enhancing their overall health and well-being.
First, in...
First, in...
3.1K
Inhaled Medications
311
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
311
Asthma: Pathogenesis and Management
446
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
446
Asthma-I: Introduction
2.7K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.7K
COPD: Management Using Bronchodilators and Corticosteroids
244
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
244


